Metastatic prostate cancer
O Sartor, JS de Bono - New England Journal of Medicine, 2018 - Mass Medical Soc
Metastatic Prostate Cancer Interventions added to androgen-deprivation therapy in men with
metastatic prostate cancer have recently been noted to increase survival. Decisions about …
metastatic prostate cancer have recently been noted to increase survival. Decisions about …
Radioactive main group and rare earth metals for imaging and therapy
TI Kostelnik, C Orvig - Chemical reviews, 2018 - ACS Publications
Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …
medicine with great success for several decades. The majority of current clinical use …
[HTML][HTML] Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, R Baum… - European journal of …, 2019 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
[HTML][HTML] Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer
A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues… - European urology, 2019 - Elsevier
Background Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer
(PC) expression has theranostic utility. Objective To elucidate PC PSMA expression and …
(PC) expression has theranostic utility. Objective To elucidate PC PSMA expression and …
Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT
M Eiber, K Herrmann, J Calais… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–ligand PET imaging provides unprecedented
accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly …
accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly …
Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA
B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti… - European urology, 2021 - Elsevier
Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with …
J Violet, P Jackson, J Ferdinandus… - Journal of Nuclear …, 2019 - Soc Nuclear Med
177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic …
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …